Fredun Pharmaceuticals has set July 16 as the record date for its 2:1 bonus issue, making today the final day for investors to purchase shares and qualify for the bonus shares. According to The Economic Times, only shareholders who hold Fredun Pharmaceuticals shares in their demat accounts as of Thursday will be eligible to receive the bonus shares. As per SEBI's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be credited to their demat accounts and qualify for the bonus issue.
The microcap pharma company's shares have demonstrated exceptional performance, jumping 84% in 2026 and nearly 200% over the past year. As reported by The Economic Times, the company currently has a market capitalisation of more than ₹1,559 crore. The stock has also delivered 590% returns over five years, reflecting sustained long-term growth momentum. Today's trading session showed the stock opening at ₹2,910.00 compared to the previous close of ₹2,857.55, with a high of ₹2,910.00 and low of ₹2,789.00. The average traded price for the day was ₹2,844.53.
Fredun Pharmaceuticals has demonstrated robust financial growth across multiple quarters. According to Moneycontrol, the company's consolidated March 2026 net sales reached ₹213.06 crore, up 28.78% year-on-year. The standalone December 2025 net sales stood at ₹159.93 crore, up 57.04% year-on-year. Earlier quarters showed consistent growth with standalone September 2025 net sales at ₹143.59 crore, up 34.33% year-on-year and standalone June 2025 net sales at ₹119.40 crore, up 54% year-on-year. The company's diversified product portfolio includes anti-bacterial, anti-malarial, and anti-diabetic tablets, capsules and dry syrups.
The company's shareholding structure as of June 2026 shows promoters holding 44.57% stake, while public investors account for 43.79% of the total shareholding. Domestic Institutional Investors (DII) hold 2.94% and Foreign Institutional Investors (FII) maintain 1.06% of the company's shares. The government holds no stake in the pharmaceutical company, as reported by The Economic Times.
Fredun Medhora, Managing Director of Fredun Pharmaceuticals, emphasized the significance of the bonus issue in a statement to The Economic Times. According to the company's management, the 2:1 bonus issue reflects strong momentum and confidence in sustaining growth trajectory. The company has also recommended a final dividend of 7% (₹0.70 per equity share) for FY26, subject to shareholder approval. The board has approved an increase in authorized share capital from ₹10 crore to ₹50 crore, while the bonus shares will be issued out of securities premium, general reserves, or retained earnings as of March 31, 2026.
